Brief: Hutchmed Says NDA Acceptance In China With Priority Review Status For Orpathys And Tagrisso Combination

HUTCHMED (China)

02/01/2025 24:01

Jan 1 (Reuters) - HUTCHMED (China) Ltd  0013.HK :
    * HUTCHMED ANNOUNCES NDA ACCEPTANCE IN CHINA WITH PRIORITY
REVIEW
STATUS FOR ORPATHYS® AND TAGRISSO® COMBINATION IN LUNG CANCER
PATIENTS WITH MET AMPLIFICATION AFTER PROGRESSION ON FIRST-LINE
EGFR INHIBITOR THERAPY
    * HUTCHMED (CHINA) LTD - THIS ACCEPTANCE ALSO TRIGGERS A
MILESTONE
PAYMENT FROM ASTRAZENECA

Source text:  ID:nGNX1YMGnt 
Further company coverage:  0013.HK 

 ((Reuters.Briefs@thomsonreuters.com;;))